AU2018351651B2 - Antagonists of the muscarinic acetylcholine receptor M4 - Google Patents

Antagonists of the muscarinic acetylcholine receptor M4 Download PDF

Info

Publication number
AU2018351651B2
AU2018351651B2 AU2018351651A AU2018351651A AU2018351651B2 AU 2018351651 B2 AU2018351651 B2 AU 2018351651B2 AU 2018351651 A AU2018351651 A AU 2018351651A AU 2018351651 A AU2018351651 A AU 2018351651A AU 2018351651 B2 AU2018351651 B2 AU 2018351651B2
Authority
AU
Australia
Prior art keywords
hexahydro
cyclopenta
pyridazin
pyrrol
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018351651A
Other languages
English (en)
Other versions
AU2018351651A1 (en
Inventor
Logan A. BAKER
Aaron M. Bender
P. Jeffrey Conn
Darren W. Engers
Julie L. Engers
Craig W. Lindsley
Kayla J. TEMPLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of AU2018351651A1 publication Critical patent/AU2018351651A1/en
Application granted granted Critical
Publication of AU2018351651B2 publication Critical patent/AU2018351651B2/en
Priority to AU2023202086A priority Critical patent/AU2023202086B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018351651A 2017-10-20 2018-10-20 Antagonists of the muscarinic acetylcholine receptor M4 Active AU2018351651B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023202086A AU2023202086B2 (en) 2017-10-20 2023-04-04 Antagonists of the muscarinic acetylcholine receptor M4

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574912P 2017-10-20 2017-10-20
US62/574,912 2017-10-20
PCT/US2018/056803 WO2019079783A1 (en) 2017-10-20 2018-10-20 ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023202086A Division AU2023202086B2 (en) 2017-10-20 2023-04-04 Antagonists of the muscarinic acetylcholine receptor M4

Publications (2)

Publication Number Publication Date
AU2018351651A1 AU2018351651A1 (en) 2020-06-04
AU2018351651B2 true AU2018351651B2 (en) 2023-01-05

Family

ID=66173904

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018351651A Active AU2018351651B2 (en) 2017-10-20 2018-10-20 Antagonists of the muscarinic acetylcholine receptor M4
AU2023202086A Active AU2023202086B2 (en) 2017-10-20 2023-04-04 Antagonists of the muscarinic acetylcholine receptor M4

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023202086A Active AU2023202086B2 (en) 2017-10-20 2023-04-04 Antagonists of the muscarinic acetylcholine receptor M4

Country Status (9)

Country Link
US (3) US11299481B2 (OSRAM)
EP (1) EP3697759A4 (OSRAM)
JP (1) JP7270989B2 (OSRAM)
KR (2) KR102776114B1 (OSRAM)
CN (2) CN118063442A (OSRAM)
AU (2) AU2018351651B2 (OSRAM)
CA (1) CA3079617A1 (OSRAM)
IL (2) IL273924B2 (OSRAM)
WO (1) WO2019079783A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114539273A (zh) 2016-06-07 2022-05-27 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
HRP20241239T1 (hr) 2017-03-23 2024-12-06 Jacobio Pharmaceuticals Co., Ltd. Novi heterociklički derivati korisni kao shp2 inhibitori
IL273428B2 (en) 2017-09-22 2023-09-01 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
CN118063442A (zh) * 2017-10-20 2024-05-24 范德比尔特大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
KR20200081424A (ko) 2017-10-31 2020-07-07 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
JP7368369B2 (ja) 2017-11-24 2023-10-24 ジュビラント・エピスクライブ・エルエルシー Ｐｒｍｔ５阻害剤としてのヘテロ環式化合物
JP7569688B2 (ja) 2017-12-22 2024-10-18 ハイバーセル，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
CN111788182B (zh) 2018-02-02 2023-09-26 范德堡大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
JP7279063B6 (ja) 2018-03-13 2024-02-15 ジュビラント プローデル エルエルシー Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物
WO2020063760A1 (en) 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
WO2021067696A1 (en) 2019-10-04 2021-04-08 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
US20230122344A1 (en) * 2019-12-10 2023-04-20 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
US20230150986A1 (en) * 2019-12-10 2023-05-18 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
MX2022010634A (es) * 2020-02-28 2023-01-19 Remix Therapeutics Inc Derivados de piridazina para modular el empalme de acidos nucleicos.
EP4139303A1 (en) * 2020-04-24 2023-03-01 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
WO2021216949A1 (en) * 2020-04-24 2021-10-28 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
EP4196473B1 (en) * 2020-08-13 2024-10-02 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
WO2022109099A1 (en) * 2020-11-18 2022-05-27 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
CN116669737A (zh) * 2020-12-22 2023-08-29 范德堡大学 毒蕈碱型乙酰胆碱受体m4的拮抗剂
KR20230124608A (ko) * 2020-12-22 2023-08-25 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
CN117120435A (zh) * 2021-04-01 2023-11-24 小野药品工业株式会社 Abhd6拮抗剂
US20240174655A1 (en) * 2021-04-02 2024-05-30 Vanderbilt University Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4
US20240228468A1 (en) * 2021-04-05 2024-07-11 Vanderbilt University N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders
JP2024532729A (ja) * 2021-08-09 2024-09-10 シロナックス リミテッド． フェロトーシス調節物質、その調製及び使用
WO2023141511A1 (en) * 2022-01-19 2023-07-27 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
JP2024052624A (ja) * 2022-09-30 2024-04-11 小野薬品工業株式会社 Ａｂｈｄ６アンタゴニストを含有する医薬組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006846A2 (en) * 2002-07-15 2004-01-22 Exelixis, Inc. Receptor-type kinase modulators and methods of use
WO2007138431A2 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
WO2008065500A2 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
WO2015119899A1 (en) * 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726172A (en) * 1996-01-16 1998-03-10 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US20040044029A1 (en) 2002-08-14 2004-03-04 Dart Michael J. Azabicyclic compounds are central nervous system active agents
AU2002347553A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CA2744997A1 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2006035280A1 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
US20090176856A1 (en) 2004-09-27 2009-07-09 Anita Mehta Muscarinic receptor antagonists
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
WO2007007281A2 (en) 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
CN101230058A (zh) * 2007-01-23 2008-07-30 上海恒瑞医药有限公司 双环氮杂烷类衍生物、其制备方法及其在医药上的用途
US8735409B2 (en) 2009-12-21 2014-05-27 Qiang Zhang Quinazoline derivatives
JP2012107001A (ja) 2010-10-22 2012-06-07 Shionogi & Co Ltd インドールアミド化合物を含有する医薬
CN103102352B (zh) 2011-11-15 2015-08-12 山东亨利医药科技有限责任公司 酪氨酸激酶抑制剂吲哚满酮衍生物
JP2016516710A (ja) 2013-03-13 2016-06-09 アッヴィ・インコーポレイテッド ピリジン系ｃｄｋ９キナーゼ阻害薬
DK3126330T3 (en) 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
HRP20210935T1 (hr) 2014-05-23 2021-08-06 F. Hoffmann - La Roche Ag Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
MY194461A (en) 2015-11-06 2022-11-30 Neurocrine Biosciences Inc N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
AU2017221404A1 (en) * 2016-02-16 2018-08-23 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
EP3541373B1 (en) * 2016-11-17 2023-11-01 Merck Sharp & Dohme LLC Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
CA3072081A1 (en) 2017-08-08 2019-02-14 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
CA3079188A1 (en) 2017-10-17 2019-04-25 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
CN118063442A (zh) * 2017-10-20 2024-05-24 范德比尔特大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
KR20200081424A (ko) * 2017-10-31 2020-07-07 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
US20230150986A1 (en) * 2019-12-10 2023-05-18 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
US20230122344A1 (en) * 2019-12-10 2023-04-20 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
WO2021216949A1 (en) * 2020-04-24 2021-10-28 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
EP4139303A1 (en) * 2020-04-24 2023-03-01 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
KR20230124608A (ko) * 2020-12-22 2023-08-25 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
US20240174655A1 (en) * 2021-04-02 2024-05-30 Vanderbilt University Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4
US20240228468A1 (en) * 2021-04-05 2024-07-11 Vanderbilt University N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders
US20240287050A1 (en) * 2021-06-11 2024-08-29 Vanderbilt University (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006846A2 (en) * 2002-07-15 2004-01-22 Exelixis, Inc. Receptor-type kinase modulators and methods of use
WO2007138431A2 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
WO2008065500A2 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
WO2015119899A1 (en) * 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds

Also Published As

Publication number Publication date
AU2023202086A1 (en) 2023-05-04
IL310346A (en) 2024-03-01
US20220213069A1 (en) 2022-07-07
AU2023202086B2 (en) 2025-04-03
US20210188820A1 (en) 2021-06-24
US11820757B2 (en) 2023-11-21
KR102776114B1 (ko) 2025-03-07
IL273924B1 (en) 2024-03-01
CA3079617A1 (en) 2019-04-25
IL273924A (en) 2020-05-31
CN118063442A (zh) 2024-05-24
IL273924B2 (en) 2024-07-01
CN111491920A (zh) 2020-08-04
WO2019079783A1 (en) 2019-04-25
JP7270989B2 (ja) 2023-05-11
US11299481B2 (en) 2022-04-12
KR20200074164A (ko) 2020-06-24
US20240116902A1 (en) 2024-04-11
EP3697759A4 (en) 2021-05-12
CN111491920B (zh) 2024-01-30
EP3697759A1 (en) 2020-08-26
JP2021500345A (ja) 2021-01-07
KR20250037575A (ko) 2025-03-17
AU2018351651A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
AU2023202086B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
EP4139303A1 (en) Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
US20230122344A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
EP4037677B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
CA3180717A1 (en) Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
US20230150986A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
EP3665175A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP2024543973A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
WO2022261427A1 (en) (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders
EP4196473A1 (en) Antagonists of the muscarinic acetylcholine receptor m4

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)